First-in-human implantation of bionic device to halt Crohn's disease (2023)

Neuronal modulation & the new device

• Linked review paper outlines gut–brain immune regulation and vagus nerve–mediated “inflammatory reflex.”
• Hope: neuromodulation could reduce or replace systemic immunosuppressants and biologics, lowering infection/cancer risk and surgery rates.
• Skepticism: likely to be an adjunct rather than replacement for biologics; unclear how much disease it can “halt” vs just reduce inflammation/scarring.

Vagus nerve stimulation (VNS) and IBD

• Some report symptom relief from non-medical “vagus nerve regulation” practices; others dismiss this as wishful thinking, especially for IBD vs IBS.
• One explanation: IBS is clearly stress–nervous-system mediated; IBD is immune-mediated, so the link seems weaker.
• Counterpoint: pilot trials of implantable VNS devices show benefit in IBD, and anecdotal correlations between stress, nerve territories, and ulcerative colitis are mentioned.
• Noninvasive VNS is already studied for other conditions (e.g., tinnitus).

Implant risks and biofilms

• Concern that long-term implants accumulate bacterial biofilms, especially on plastics.
• Clarification that the device likely sits near nerves rather than inside the gut lumen, but commenters note most implants eventually develop some kind of biofilm due to normal body flora.

Biologics, steroids, and risk tradeoffs

• Debate on cancer risk from TNF inhibitors: early warnings vs later registry/meta-analytic data suggesting no major additional cancer risk; funding sources prompt skepticism.
• Broad agreement that:
  • All systemic immune-targeting drugs increase infection risk.
  • Long-term data on newer agents is limited.
  • Chronic uncontrolled inflammation itself strongly raises cancer and complication risk.
• Anecdotes of severe adverse events (anaphylaxis, rapid pneumonia→sepsis, stroke/cancer concerns).
• Thiopurines and anti-TNFs increase lymphoma/skin cancer risk, especially in combination; integrin antagonists noted as not linked to cancer in one comment.
• Prednisone is widely viewed as effective but dangerous long-term (osteoporosis, joint damage); still used when nothing else works.

Diet, microbiome, and heterogeneity

• Multiple personal stories: water-only fasting, paleo/“clean” diets, allergen elimination, low-fiber or “junk food” diets, Mediterranean focus, and highly individualized trigger foods.
• Strong consensus that:
  • Crohn’s manifestations vary by gut location and type (e.g., stricturing), so dietary responses are highly individual.
  • Many patients experiment extensively; adherence to strict diets is hard, so clinicians often discount dietary therapies.
• Proposals for ML/AI on diet–symptom logs are met with reminders of nonlinear biology and low-quality dietary data.

Etiology, environment, and epidemiology

• Noted pattern: IBD incidence rises with national development; immigrants from low-incidence regions keep low risk, but their children in high-income countries show elevated risk.
• Hypotheses discussed: microbiome disruption, hygiene, low fiber, pollution, food processing/herbicides, smoking/nicotine, heavy antibiotic use in infancy, breastfeeding patterns, and vaccines (the latter raised contentiously, without consensus).
• Australia cited as high-incidence; calls to investigate environmental and supply-chain factors.

Medicine, “band-aids,” and cures

• Some frustration that many therapies manage symptoms instead of curing root causes.
• Others defend medical conservatism: high stakes discourage unorthodox experimentation; new drugs undergo long development, and untreated disease has known severe harms.
• Hope that bioelectronic medicine and future tools (including AI and gene editing) might move from “band-aids” toward true disease modification or cures.